METHODS: Between March 2013 and October 2015, we enrolled a total of 100 patients who were diagnosed with
small cell lung cancer and scheduled for
platinum-based
chemotherapy. Patients were randomly assigned to two groups: the
music therapy group (received six-step
music therapy, n=50) and the control group (not received six-step
music therapy, n=50). The anxiety,
pain, and sleep quality of all patients were assessed using the self-rating anxiety scale (SAS), the visual analogue scale (VAS), and the Pittsburgh Sleep Quality Index (PSQI), respectively.
RESULTS: There were no significant differences in the demographic characteristics and music background between the two groups. The SAS and VAS scores in the two groups were not statistically different before
chemotherapy. However, patients in the
music therapy group showed significantly lower SAS and VAS scores compared with the control group at both 1 day and 5 days after
chemotherapy. (SAS score at 1-day post-
therapy, 49.48±2.14 vs 61.46±8.8, P=0.011; SAS score at 5-day post-
therapy, 39.73±1.79 vs 62.02±8.83, P=0.005; VAS score at 1-day post-
therapy, 2.14±0.78 vs 4.74±1.01, P=0.005; VAS score at 5-day post-
therapy, 2.06±0.79 vs 4.74±1.08, P=0.004). In addition, the total PSQI score of patients who received
music therapy was also significantly higher than that of the control group after
therapy (total PSQI score at 1-day post-
therapy, 8.50±1.69 vs 17.81±3.01, P=0.006; total PSQI score at 5-day post-
chemotherapy, 9.84±3.02 vs 18.66±2.91, P=0.012).
CONCLUSION: Chinese Clinical Trial Registry (registration number: ChiCTR-TRC-13003993).